Acquisitions2 April 2026 at 05:35 am
Lupin Completes Acquisition of VISUfarma, Expanding Specialty Care Portfolio and European Presence
AI Summary
Global pharma major Lupin Limited announced the completion of its acquisition of VISUfarma B.V., a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP. The acquisition significantly expands Lupin’s specialty care portfolio and strengthens its presence in Europe, adding a differentiated portfolio of more than 60 innovative eye health products and a strong commercial footprint across key European markets. The acquisition is immediately accretive and accelerates the build-out of Lupin’s specialty franchise.
Key Highlights
- Lupin Limited acquires VISUfarma B.V., a leading European specialty pharmaceutical company focused on ophthalmology.
- The acquisition significantly expands Lupin’s specialty care portfolio and strengthens its presence in Europe.
- VISUfarma’s strong commercial footprint across key European markets includes Italy, the UK, Spain, Germany, and France.
- The acquisition adds a differentiated portfolio of more than 60 innovative eye health products to Lupin’s portfolio.
- The acquisition is immediately accretive and accelerates the build-out of Lupin’s specialty franchise.
LUPINPharmaceuticals
LUPIN LTD.Price Impact